If you’ve been thinking about starting a GLP-1 medication for weight loss, there’s a question that often comes up sooner or later: What happens when I stop taking it?
Maybe you’ve heard that GLP-1 medications are something you have to take forever. Or maybe you assumed you’d take them until you reached your goal weight, then stop.
Neither idea tells the whole story.
Medications such as Semaglutide and Tirzepatide are used as part of long-term obesity treatment. For many people, maintaining the weight they’ve lost may require continuing treatment after reaching their goal. But the right long-term plan depends on how well the medication is working, side effects, health goals, cost, preferences, and what happens when treatment is reduced or stopped. The American Diabetes Association’s 2026 guidance describes obesity as a chronic, often relapsing disease and recommends continuing obesity medications indicated for chronic therapy beyond weight-loss goals when appropriate.
Why does weight come back after stopping?
Losing weight changes more than the number on the scale.
As body weight decreases, the body can respond with changes in appetite and energy regulation that make maintaining the lower weight difficult. This is one reason obesity can behave like other chronic conditions that need ongoing management rather than a problem that is permanently “fixed” after one period of treatment.
GLP-1 medications help influence appetite, food intake, and other metabolic processes while you’re taking them. When the medication is removed, some of those effects go away.
Clinical trials have shown what this can look like. In the STEP 1 extension study, people who stopped semaglutide after 68 weeks regained a substantial amount of the weight they had lost during the following year. Participants regained an average of 11.6 percentage points of their lost weight by week 120, equivalent to about two-thirds of their previous weight loss. Improvements in several cardiometabolic measurements also moved back toward baseline.
Similar findings have been seen with Tirzepatide. In the SURMOUNT-4 trial, people who stopped Tirzepatide after an initial 36 weeks of treatment regained a substantial amount of weight over the following year, while those who continued treatment maintained and extended their weight reduction. The participants who switched to placebo regained an average of 14% of their body weight during the 52-week withdrawal period, while those who continued Tirzepatide lost an additional 5.5%.
A later analysis of SURMOUNT-4 found that about 82% of participants who stopped Tirzepatide regained at least 25% of the weight they had initially lost within one year. Greater weight regain was also associated with greater reversal of improvements in several cardiometabolic measures.
That doesn’t mean everyone who stops a GLP-1 will regain all of their weight. Individual responses vary. It does show why stopping treatment isn’t necessarily the same thing as finishing treatment.
Does that mean you have to stay on the highest dose forever?
No. Long-term treatment doesn’t automatically mean staying on the maximum dose indefinitely.
The American Diabetes Association recommends individualizing the maintenance dose based on effectiveness, health benefits, and tolerability. The dose used for maintenance may be lower than the maximum approved dose. Depending on the person and circumstances, clinicians may consider continuing at an individualized maintenance dose, adjusting treatment, switching medications, or stopping treatment with close monitoring.
This is also why reaching a goal weight doesn’t necessarily mean there’s no reason to continue treatment.
If someone has lost weight, their blood sugar or other health markers have improved, and they’re tolerating the medication well, continuing treatment may help maintain those benefits. The goal shifts from losing more weight to maintaining the progress that has already been made.
For someone else, the balance may look different. Side effects, cost, medication access, personal preference, or other health considerations can all influence the decision.
There’s no universal number of months or years that applies to everyone.
What if you want to stop?
Stopping a GLP-1 is something to discuss with your healthcare provider rather than deciding on your own.
Your provider can look at why you want to stop and what your options are. If side effects are the problem, there may be ways to adjust the dose or treatment. If cost or access is the issue, another medication or treatment approach may be possible. If you’ve reached your weight goal and want to see whether you can maintain it without medication, your provider can help you make a plan for monitoring what happens next.
The important part is having a plan for maintenance.
The ADA recommends ongoing monitoring after weight loss and notes that long-term weight-maintenance programs include continued support, self-monitoring, and regular physical activity. If medication is stopped, close monitoring can help identify weight regain early and give you an opportunity to adjust your treatment plan.
And if some weight comes back, that isn’t a personal failure. Weight regain after stopping obesity medication is a documented response seen in clinical research. It doesn’t mean you lacked discipline or that the treatment “didn’t work.” It may simply mean that ongoing treatment is part of what helps your body maintain the weight you achieved.
For some people, that may mean taking a GLP-1 long term. For others, it may mean changing the medication, using a different maintenance strategy, or eventually stopping with medical supervision.
So, do you have to take a GLP-1 forever?
Not necessarily. But if a GLP-1 is being used as part of chronic obesity treatment, long-term treatment may be necessary to maintain the benefits for some people.
The decision shouldn’t be based on a fixed timeline or the idea that reaching a certain number on the scale means treatment is automatically finished. It should be based on what happens to your weight, appetite, health markers, side effects, and overall well-being over time.
If you’re considering stopping a GLP-1, talk with your healthcare provider before making the change. Together, you can decide whether continuing, adjusting, switching, or stopping treatment makes the most sense for you.
Sources
- American Diabetes Association — Standards of Care in Diabetes—2026: Obesity and Weight Management
https://doi.org/10.2337/dc26-s008 - American Diabetes Association — Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
https://doi.org/10.2337/doci25-0008 - Wilding JP, et al. — Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
https://pubmed.ncbi.nlm.nih.gov/35441470/ - Aronne LJ, et al. — Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
https://jamanetwork.com/journals/jama/fullarticle/2812936 - Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial
https://doi.org/10.1001/jamainternmed.2025.6112
Related Articles
This article is general educational information and is not medical advice. Retatrutide remains investigational and is not currently FDA-approved for routine use. It does not replace guidance from your prescriber or pharmacist. Talk with a qualified healthcare professional before starting, stopping, or changing any medication.
